Pfizer announced the election of Dr. Dan R. Littman to its Board of Directors. Littman was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.
Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an Investigator of the Howard Hughes Medical Institute. Prior to joining NYU in 1995, he was a Professor of Microbiology and Immunology at the University of California, San Francisco.
Littman is also a member of the National Academy of the Sciences and the Institute of Medicine, and is a Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.
Littman received an A.B. in Biochemical Sciences from Princeton University and an M.D. and Ph.D. from Washington University School of Medicine.
“We are pleased to welcome a renowned immunologist to Pfizer’s Board of Directors,” said Ian Read, Chairman and Chief Executive Officer, Pfizer. “Dr. Littman has made extraordinary scientific contributions throughout his career and will be a tremendous asset to the company. The addition of Dan to the board helps to ensure that Pfizer will continue to benefit from a breadth and diversity of experience.”